New Evidence May Pave Way For Proving Exposure To Tobacco Smoke Has Caused An Individual's Cancer

March 31, 1998

Researchers have moved a significant step closer to proving a molecular connection between tobacco smoke and one of the key factors associated with some cases of lung cancer: specific mutations in the p53 tumor-suppressor gene of lung cells.

The finding requires further study, says lead author John Wiencke, PhD, a UC San Francisco associate professor of epidemiology. However, it lays the groundwork for developing a means of determining whether a given individual has developed lung cancer as a result of exposure to tobacco smoke--even second-hand smoke. The investigation, conducted by UCSF's Wiencke and colleagues at Harvard Medical School and Massachusetts General Hospital, was presented here today (March 31) at the American Association for Cancer Research meeting.

Scientists have known for several years that there is a strong "association" between the specific pattern of mutations often seen in the p53 tumor-suppressor gene of lung cancer cells and exposure to tobacco smoke. But until now they have not had hard evidence that tobacco smoke actually caused these mutations.

Previous studies in lab cultured cells have demonstrated that the carcinogens in tobacco smoke known as polynuclear aromatic hydrocarbons (PAHs) physically bind to the p53 gene in so-called "hot spots," forming physical complexes, or chemical modifications, called DNA adducts. Adducts are one of the first steps in the carcinogenic pathway that ultimately leads to tumor formation.

Given these findings, scientists have suspected that DNA adducts were the actual cause of the p53 mutations. However, because they could not literally peer into the human lung and document cigarette carcinogens creating mutations in the p53 gene, they could not prove it.

In the current study, the researchers have worked around this roadblock--and have done so in humans.

In a study of 137 currently smoking, non-small cell lung cancer patients at Massachusetts General Hospital, the scientists examined whether increased levels of PAH DNA adducts, were associated with the occurrence of p53 mutations.

They did so by assessing the DNA adduct levels in each of the patients' non-cancerous lung tissue, and scrutinizing the same patients' tumors for evidence of p53 mutations. They found that people with increased adduct levels in their lungs were three times more likely to have p53 mutations in their lung cancer cells. This group accounted for 38 of the patients.

While the researchers still have to demonstrate that the p53 mutations identified in the patients have the specific pattern, or "fingerprint," associated with the PAH tobacco carcinogen, the immediate finding is itself compelling, says Wiencke.

"Until now, the only association between PAH DNA adducts and p53 mutations had been demonstrated in cultured cells in the laboratory," says Wiencke. "This is the first strong evidence that DNA adducts are the causal link between the tobacco smoke and the mutation. Our study supports the proposal that p53 fingerprinting may be useful for identifying specific causes of cancer."

The researchers also observed that DNA adduct levels varied in the 137 patients by as much as 30-fold, and the disparity could not be explained by levels of exposure to cigarette smoke (e.g., number of cigarettes smoked per day or number of years smoked).

"This enormous variation in DNA adduct levels observed between patients suggests that people respond very differently to the different carcinogens in tobacco," says Wiencke.

"There are likely to be several distinct mechanisms, or pathways, by which smoking causes lung cancer," he explains, "one involving PAHs and the p53 gene, and others involving different classes of carcinogens (e.g., nitrosamines), which may target genes other than p53. Different parts of the smoking carcinogens affect different people."

"Our findings," says Wiencke, "suggest that measuring the adduct levels in lung cancer patients is superior to taking a smoking exposure history in predicting which patients will develop p53 abnormalities."

The researchers have subsequently found a close correlation between DNA adduct levels in the lung and white blood cell levels. Eventually, says Wiencke, it may be possible to predict DNA adduct levels in the lung--and thus the likelihood of a person developing p53 mutations--by assessing the blood.

"Such a test may allow us to predict which smokers are at greatest risk for developing lung cancer," he says.

"We only expect this research on DNA adducts to get stronger and better," says Wiencke. "We already have an association that is very significant, so it will be hard for this to go away."
-end-


University of California - San Francisco

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.